M. Scott Lucia, MD

M. Scott Lucia, MD

University of Colorado, Denver

Aurora, Colorado

M. Scott Lucia, MD, is Professor and Vice Chair of the Department of Pathology and Director of Anatomic Pathology and of the Prostate Diagnostic Laboratory at the University of Colorado Anschutz Medical Campus (UCAMC) School of Medicine. He also serves as the Director of the Prostate Cancer Research Laboratories at UCAMC and of the UCAMC Biorepository Core Facility. Dr. Lucia received his MD from the University of Colorado School of Medicine in 1988. He completed his internship and residency in pathology at the University of Colorado in 1993. He was a research fellow in the Laboratory of Chemoprevention at the National Institutes of Health from 1993 to 1995, before returning to the University of Colorado in 1995. Dr. Lucia served as the primary pathologist for the Prostate Cancer Prevention Trial (PCPT) and Vitamin E and Selenium Chemoprevention Trial (SELECT), sponsored by the Southwest Oncology Group; the Medical Therapy of Prostate Symptoms (MTOPS) trial, sponsored by the NIDDK; and the Reduction with Dutasteride of Clinical Progression Events in Expectant Management of Prostate Cancer (REDEEM), sponsored by GlaxoSmithKline. He directs the operation of several tissue and serum biorepositories for prostate and prostatic diseases, including those for the PCPT, MTOPS, SELECT, and the University of Colorado Cancer Center Prostate Biorepository. He has authored or co-authored over 180 peer-reviewed articles, reviews, editorials, and book chapters. His primary areas of interest include pathology of prostate cancer and hyperplasia, early detection and prevention of prostate cancer, prostate cancer biomarkers, and mechanisms of carcinogenesis.


Articles by M. Scott Lucia, MD

Progress in Prostate Cancer Grading

M. Scott Lucia, MD, reviews the historical utilization of the Gleason grading score as an indicator of prostate cancer prognosis and the refinements the system has undergone to improve predictive accuracy. He examines changes to the grading of cribriform carcinoma, as well as an improved 5-tier grade classification system.

Read More

Pathologist’s Perspective on Focal Therapy

M. Scott Lucia, MD, defines the ideal candidate for targeted focal therapy of the prostate. He discusses the limitations of transrectal ultrasound- and multiparametric MRI-guided biopsies for determining focal therapy eligibility, as well as evidence regarding template-guided transperitoneal mapping biopsies for improved tumor assessment.

Read More

FDUS 2018 – Next Generation in Biomarkers

M. Scott Lucia, MD, led the “Next Generation in Biomarkers” session at the Future Directions in Urology Symposium (FDUS) 2018. These consensus statements represent a comprehensive analysis of current issues, challenges, and advancements in urology from a panel of international experts.

Read More

Join the GRU Community

- Why Join? -